Shyamal Palit1, Michel Chonchol1, Alfred K Cheung2, James Kaufman3, Gerard Smits1, Jessica Kendrick4. 1. Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, Colorado; 2. Division of Nephrology & Hypertension, University of Utah, Salt Lake City, Utah; Renal Section, Medical Service, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah; and. 3. Research Service, Veterans Affairs New York Harbor Healthcare System and Department of Medicine, New York University School of Medicine, New York, New York. 4. Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, Colorado; Jessica.Kendrick@ucdenver.edu.
Abstract
BACKGROUND AND OBJECTIVE: The optimal BP target to reduce adverse clinical outcomes in patients with CKD is unclear. This study examined the relationship between BP and death, cardiovascular events (CVEs), and kidney disease progression in patients with advanced kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The relationship of systolic BP (SBP), diastolic BP (DBP), and pulse pressure (PP) with death, CVE, and progression to long-term dialysis was examined in 1099 patients with advanced CKD (eGFR≤30 ml/min per 1.7 3m(2); not receiving dialysis) who participated in the Homocysteine in Kidney and ESRD study. That study enrolled participants from 2001 to 2003. Cox proportional hazard models were used to examine the association between BP and adverse outcomes. RESULTS: The mean±SD baseline eGFR was 18±7 ml/min per 1.73 m(2). During a median follow-up of 2.9 years, 453 patients died, 215 had a CVE, and 615 initiated long-term dialysis. After adjustment for demographic characteristics and confounders, SBP, DBP, and PP were not associated with a higher risk of death. SBP and DBP were also not associated with CVE. The highest quartile of PP was associated with a substantial higher risk of CVE compared with the lowest quartile (hazard ratio [HR], 1.67; 95% confidence interval [95% CI], 1.10 to 2.52). The highest quartiles of SBP (HR, 1.28; 95% CI, 1.01 to 1.61) and DBP (HR, 1.36; 95% CI, 1.07 to 1.73), but not PP, were associated with a higher risk of progression to long-term dialysis compared with the lowest quartile. CONCLUSIONS: In patients with advanced kidney disease not undergoing dialysis, higher PP was strongly associated with CVE whereas higher SBP and DBP were associated with progression to long-term dialysis. These results suggest that SBP and DBP should not be the only factors considered in determining antihypertensive therapy; elevated PP should also be considered.
RCT Entities:
BACKGROUND AND OBJECTIVE: The optimal BP target to reduce adverse clinical outcomes in patients with CKD is unclear. This study examined the relationship between BP and death, cardiovascular events (CVEs), and kidney disease progression in patients with advanced kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The relationship of systolic BP (SBP), diastolic BP (DBP), and pulse pressure (PP) with death, CVE, and progression to long-term dialysis was examined in 1099 patients with advanced CKD (eGFR≤30 ml/min per 1.7 3m(2); not receiving dialysis) who participated in the Homocysteine in Kidney and ESRD study. That study enrolled participants from 2001 to 2003. Cox proportional hazard models were used to examine the association between BP and adverse outcomes. RESULTS: The mean±SD baseline eGFR was 18±7 ml/min per 1.73 m(2). During a median follow-up of 2.9 years, 453 patients died, 215 had a CVE, and 615 initiated long-term dialysis. After adjustment for demographic characteristics and confounders, SBP, DBP, and PP were not associated with a higher risk of death. SBP and DBP were also not associated with CVE. The highest quartile of PP was associated with a substantial higher risk of CVE compared with the lowest quartile (hazard ratio [HR], 1.67; 95% confidence interval [95% CI], 1.10 to 2.52). The highest quartiles of SBP (HR, 1.28; 95% CI, 1.01 to 1.61) and DBP (HR, 1.36; 95% CI, 1.07 to 1.73), but not PP, were associated with a higher risk of progression to long-term dialysis compared with the lowest quartile. CONCLUSIONS: In patients with advanced kidney disease not undergoing dialysis, higher PP was strongly associated with CVE whereas higher SBP and DBP were associated with progression to long-term dialysis. These results suggest that SBP and DBP should not be the only factors considered in determining antihypertensive therapy; elevated PP should also be considered.
Authors: Daniel E Weiner; Hocine Tighiouart; Andrew S Levey; Essam Elsayed; John L Griffith; Deeb N Salem; Mark J Sarnak Journal: J Am Soc Nephrol Date: 2007-02-14 Impact factor: 10.121
Authors: L G Hunsicker; S Adler; A Caggiula; B K England; T Greene; J W Kusek; N L Rogers; P E Teschan Journal: Kidney Int Date: 1997-06 Impact factor: 10.612
Authors: F K Port; T E Hulbert-Shearon; R A Wolfe; W E Bloembergen; T A Golper; L Y Agodoa; E W Young Journal: Am J Kidney Dis Date: 1999-03 Impact factor: 8.860
Authors: Debasish Banerjee; Stephan Brincat; Helen Gregson; Gabriel Contreras; Chris Streather; David Oliveira; Stephen Nelson Journal: Nephrol Dial Transplant Date: 2005-12-29 Impact factor: 5.992
Authors: K Iseki; F Miyasato; K Tokuyama; K Nishime; H Uehara; Y Shiohira; H Sunagawa; K Yoshihara; S Yoshi; S Toma; T Kowatari; T Wake; T Oura; K Fukiyama Journal: Kidney Int Date: 1997-04 Impact factor: 10.612
Authors: P G Zager; J Nikolic; R H Brown; M A Campbell; W C Hunt; D Peterson; J Van Stone; A Levey; K B Meyer; M J Klag; H K Johnson; E Clark; J H Sadler; P Teredesai Journal: Kidney Int Date: 1998-08 Impact factor: 10.612
Authors: Carmen A Peralta; Michael G Shlipak; Christina Wassel-Fyr; Hayden Bosworth; Brian Hoffman; Susana Martins; Eugene Oddone; Mary K Goldstein Journal: Hypertension Date: 2007-07-30 Impact factor: 10.190
Authors: Morgan E Grams; Wei Yang; Casey M Rebholz; Xue Wang; Anna C Porter; Lesley A Inker; Edward Horwitz; James H Sondheimer; L Lee Hamm; Jiang He; Matthew R Weir; Bernard G Jaar; Tariq Shafi; Lawrence J Appel; Chi-Yuan Hsu Journal: Am J Kidney Dis Date: 2017-03-30 Impact factor: 8.860
Authors: Nisha Bansal; Charles E McCulloch; Feng Lin; Cassianne Robinson-Cohen; Mahboob Rahman; John W Kusek; Amanda H Anderson; Dawei Xie; Raymond R Townsend; Claudia M Lora; Jackson Wright; Alan S Go; Akinlolu Ojo; Arnold Alper; Eva Lustigova; Magda Cuevas; Radhakrishna Kallem; Chi-Yuan Hsu Journal: Kidney Int Date: 2016-10-04 Impact factor: 10.612
Authors: Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani Journal: Cochrane Database Syst Rev Date: 2020-02-27